{"id":"W2102177981","doi":"10.1177/1753465812470018","title":"Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective","year":2013,"lang":"en","type":"review","venue":"Therapeutic Advances in Respiratory Disease","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Public Health Agency of Canada; Novartis Pharmaceuticals Corporation; AstraZeneca","keywords":"Indacaterol; Medicine; COPD; Tolerability; Placebo; Bronchodilator; Salmeterol; Internal medicine; Confidence interval; Minimal clinically important difference; Adverse effect; Randomized controlled trial; Anesthesia; Asthma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009638003,0.000356814,0.000854629,0.0007110304,0.0002048715,0.0008369213,0.0003946561,0.0008309511,0.00299879],"category_scores_gemma":[0.0009624904,0.0001505823,0.0007138736,0.000916185,0.000248479,0.0007394119,0.0002025724,0.001435344,0.0009096265],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003973553,"about_ca_system_score_gemma":0.001123925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001722994,"about_ca_topic_score_gemma":0.005903239,"domain_scores_codex":[0.999712,0.00009040046,0.00004177566,0.00003378853,0.0001044658,0.00001737796],"domain_scores_gemma":[0.9993308,0.0002454978,0.0001648686,0.000009930655,0.0001920335,0.00005690616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001058825,0.0002521069,0.0008092604,0.0208366,0.0004810737,0.0002562334,0.0001611207,0.0001748667,0.003237965,0.001916104,0.0463984,0.9244174],"study_design_scores_gemma":[0.0008830021,0.002578638,0.01049581,0.01371899,0.002041445,0.003245279,0.0002449184,0.0002298331,0.0007444525,0.00116346,0.9645998,0.00005443438],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008741478,0.9945509,0.00008600284,0.002126867,0.000375008,0.000007419846,0.00002910261,0.000008219046,0.001942249],"genre_scores_gemma":[0.006943448,0.9882908,0.000279742,0.002568091,0.0007212999,0.00001789234,0.00003933624,0.000003020923,0.001136282],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00299879,"threshold_uncertainty_score":0.010032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03516204505204169,"score_gpt":0.3586399126017456,"score_spread":0.3234778675497039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}